Inhibition of osteoblastic bone formation by nuclear factor-B

Nature Medicine

Volumn 15, Issue 6, 2009, Pages 682-689

  Chang, Jia ^a   Wang, Zhuo ^b   Tang, Eric ^a   Fan, Zhipeng ^a   McCauley, Laurie ^c,d   Franceschi, Renny ^c   Guan, Kunliang ^e   Krebsbach, Paul H ^b   Wang, Cun Yu ^a  

^a UNIVERSITY OF CALIFORNIA   (United States)

^b UNIVERSITY OF MICHIGAN   (United States)

^c UNIVERSITY OF MICHIGAN SCHOOL OF DENTISTRY   (United States)

^d UNIVERSITY OF MICHIGAN MEDICAL SCHOOL   (United States)

^e UNIVERSITY OF CALIFORNIA   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

I KAPPA B KINASE INHIBITOR; IMMUNOGLOBULIN ENHANCER BINDING PROTEIN; TRANSCRIPTION FACTOR FRA 1;

ANIMAL EXPERIMENT; ANIMAL MODEL; ARTICLE; BONE DENSITY; BONE DEVELOPMENT; BONE MASS; CELL ACTIVITY; CELL DIFFERENTIATION; CONTROLLED STUDY; MOUSE; NONHUMAN; OSSIFICATION; OSTEOBLAST; OSTEOLYSIS; OSTEOPOROSIS; OVARIECTOMY; PRIORITY JOURNAL; TRABECULAR BONE;

ANIMALS; CELL DIFFERENTIATION; CELL LINE; FEMALE; HUMANS; MICE; MICE, TRANSGENIC; NF-KAPPA B; OSTEOBLASTS; OSTEOGENESIS; OSTEOPOROSIS; OVARIECTOMY; PROTO-ONCOGENE PROTEINS C-FOS;

MUS;

EID: 67349238305     PISSN: 10788956     EISSN: 1546170X     Source Type: Journal    
DOI: 10.1038/nm.1954     Document Type: Article

References (35)

1. Wagner, E.F. & Karsenty, G. Genetic control of skeletal development. Curr. Opin. Genet. Dev. 11, 527-532 (2001).
2. Khosla, S., Westendorf, J.J. & Oursler, M.J. Building bone to reverse osteoporosis and repair fractures. J. Clin. Invest. 118, 421-428 (2008).
3. Zaidi, M. Skeletal remodeling in health and disease. Nat. Med. 13, 791-801 (2007).
4. Clowes, J.A., Riggs, B.L. & Khosla, S. The role of the immune system in the pathophysiology of osteoporosis. Immunol. Rev. 208, 207-227 (2005).
5. Raisz, L.G. Pathogenesis of osteoporosis: concepts, conflicts, and prospects. J. Clin. Invest. 115, 3318-3325 (2005).
6. Weitzmann, M.N. & Pacifici, R. Estrogen deficiency and bone loss: an inflammatory tale. J. Clin. Invest. 116, 1186-1194 (2006).
7. Teitelbaum, S.L. & Ross, F.P. Genetic regulation of osteoclast development and function. Nat. Rev. Genet. 4, 638-649 (2003).
8. Khosla, S. & Riggs, B.L. Pathophysiology of age-related bone loss and osteoporosis. Endocrinol. Metab. Clin. North Am. 34, 1015-1030 (2005).
9. Ghosh, S. & Karin, M. Missing pieces in the NF-κB puzzle. Cell 109, S81-S96 (2002).
10. Chen, Z.J. Suppression of tumor necrosis factor-mediated apoptosis by nuclear factor κB-independent bone morphogenetic protein/Smad signaling. Nat. Cell Biol. 7, 758-765 (2005).
11. Huang, T.T. et al. Sequential modification of NEMO/IKKγ by SUMO-1 and ubiquitin mediates NF-κB activation by genotoxic stress. Cell 115, 565-576 (2003).
12. Li, Q. & Verma, I.M. NF-κB regulation in the immune system. Nat. Rev. Immunol. 2, 725-734 (2002).
13. Silverman, N. & Maniatis, T. NF-kB signaling pathways in mammalian and insect innate immunity. Genes Dev. 15, 2321-2342 (2001).
14. Guttridge, D.C. et al. NF-kappa;B activation induces the loss of MyoD mRNA: implications for cytokine-induced skeletal muscle dysfunction and cachexia. Science 289, 2363-2366 (2000).
15. Jimi, E. et al. Selective inhibition of NF-kappa;B blocks osteoclastogenesis and prevents inflammatory bone destruction in vivo. Nat. Med. 10, 617-624 (2004).
16. Ruocco, M.G. et al. Ikappa;B kinase (IKK)β, but not IKKα, is a critical mediator of osteoclast survival and is required for inflammation-induced bone loss. J. Exp. Med. 201, 1677-1687 (2005).
17. Tang, E.D. et al. A role for NF-(B essential modifier/I(B kinase-((NEMO/IKK() ubiquitination in the activation of the I(B kinase complex by tumor necrosis factor-α. J. Biol. Chem. 278, 37297-37305 (2003).
18. Yang, F. et al. The zinc finger mutation C417R of I-kappa; B kinase gamma; impairs lipopolysaccharide-and TNF-mediated NF-kappa; B activation through inhibiting phosphorylation of the I-kappa; B kinase β activation loop. J. Immunol. 172, 2446-2452 (2004).
19. Wang, C.-Y. et al. TNF-and cancer therapy - induced apoptosis: potentiation by inhibition of NF-kappa;B. Science 274, 784-787 (1996).
20. Park, B.K. et al. NF-kappa;B in breast cancer cells promotes osteolytic bone metastasis by inducing osteoclastogenesis via GM-CSF. Nat. Med. 13, 62-69 (2007).
21. Wang, C.-Y. et al. Control of inducible chemoresistance: enhanced anti-tumor therapy via increased apoptosis through inhibition of NF-kappa;B. Nat. Med. 5, 412-417 (1999).
22. Ducy, P. et al. A Cbfa1-dependent genetic pathway controls bone formation beyond embryonic development. Genes Dev. 13, 1025-1036 (1999).
23. Frendo, J.L. et al. Functional hierarchy between two OSE2 elements in the control of osteocalcin gene expression in vivo. J. Biol. Chem. 273, 30509-30516 (1998).
24. Bilic-Curcic, I. et al. Visualizing levels of osteoblasts differentiation by two-color promoter-GFP strategy:tType I collagen-GFPcyan and osteocalcin-GFPtpz. Genesis 43, 87-98 (2005).
25. Ge, C. et al. Critical role of the extracellular signal-regulated kinase-MAPK pathway in osteoblast differentiation and skeletal development. J. Cell Biol. 176, 709-718 (2007).
26. Li, Y.P. & Stashenko, P. Characterization of a tumor necrosis factor-responsive element which down-regulates the human osteocalcin gene. Mol. Cell. Biol. 13, 3714-3721 (1993).
27. De Smaele, E. et al. Induction of gadd45β by NF-kappa;B downregulates pro-apoptotic JNK signaling. Nature 414, 308-313 (2001).
28. Tang, G. et al. Inhibition of JNK activation through NF-kappa;B target genes. Nature 414, 313-317 (2001).
29. Reuther-Madrid, J.Y. et al. The p65/RelA subunit of NF-kappa;B suppresses the sustained, antiapoptotic activity of Jun kinase induced by tumor necrosis factor. Mol. Cell. Biol. 22, 8175-8183 (2002).
30. Yamashita, M. et al. Ubiquitin ligase smurf1 controls osteoblast activity and bone homeostasis by targeting MEKK2 for degradation. Cell 121, 101-113 (2005).
31. Jochum, W. et al. Increased bone formation and osteosclerosis in mice overexpressing the transcription factor Fra-1. Nat. Med. 6, 980-984 (2000).
32. Sabatakos, G. et al. Overexpression of ΔFosB transcription factor(s) increases bone formation and inhibits adipogenesis. Nat. Med. 6, 985-990 (2000).
33. Eferl, R. et al. The Fos-related antigen Fra-1 is an activator of bone matrix formation. EMBO J. 23, 2789-2799 (2004).
34. Harnish, D.C. Estrogen receptor ligands in the control of pathogenic inflammation. Cur. Opin. Investig. Drugs 7, 997-1001 (2006).
35. Pearse, R.N. Wnt antagonism in multiple myeloma: a potential cause of uncoupled bone remodeling. Clin. Cancer Res. 12, 6274s-6278s (2006).